Replies to post #671762 on NorthWest Biotherapeutics Inc (NWBO)

[skitahoe]

Thanks Biosect,

I might be very surprised, but my feeling is that in different cancers Oncologists will experiment and find that DCVax-L is a benefit, but the synergy with other products are different, not Poly-ICLC and/or Keytruda for all. While I'm sure the developers of Poly-ICLC would be thrilled to find it works in many cancers, frankly I think they're very happy to have it tied to DCVax-L in brain cancers as that alone will make their company successful.

Curing cancer in many ways is a foolish expression, it's not one disease, with all the ways it mutates, its forms probably approach infinity. The fact that we're using the patients cancer to fight itself seems to me like a great approach, but certainly not one that will cure every patient. I suppose if the cancer returns, the best treatment may be making new DCVax-L as the cancer may have mutated since the original vaccine was created. I don't know if this was done at all during the trial.

I know that sometimes when a patient becomes refractory to the SOC treatment with other products may not be effective for long, but returning to the SOC may prove effective and alternating treatment may be the answer to much longer life, even if you cannot achieve a cure.

Gary